| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.071 | 0.01 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.02 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.12 | 0.03 |